+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptide Therapeutics Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Peptide, Route of Administration, Key Therapeutic Area and Geographical Regions- Product Image
Peptide Therapeutics Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Peptide, Route of Administration, Key Therapeutic Area and Geographical Regions- Product Image
New

Peptide Therapeutics Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Peptide, Route of Administration, Key Therapeutic Area and Geographical Regions

  • PDF Icon

    Report

  • 250 Pages
  • December 2025
  • Region: Global
  • Roots Analysis
  • ID: 6214397
Description Jump to:
The peptide therapeutics market is estimated to grow from USD 84.2 billion in the current year to USD 162.4 billion by 2035, at a CAGR of 6.8% during the forecast period, till 2035.

PEPTIDE THERAPEUTICS MARKET: GROWTH AND TRENDS

Peptide therapeutics are a class of medications developed with polypeptides to cater to various illnesses. Generally, naturally occurring peptides can serve as growth factors, hormones, neurotransmitters, anti-infectives, and ligands for ion channels. Such peptides have been utilized in creating peptide-based therapies that are commonly employed in treating metabolic diseases, cancer, and hormone-related treatments. It is noteworthy that more than 100 peptide-based therapies have been authorized by the FDA in various nations.

Examples of recognized peptide therapeutics include Tirzepatide (Mounjaro®), Lutetium Lu-177 vipivotide tetraxetan (Pluvicto®), and Lupkynis™. Driven by the rising prevalence of chronic conditions, such as diabetes, osteoarthritis, obesity, autoimmune disorders, rheumatoid arthritis, and cancer, an increased demand for biologics in disease treatment has been observed in recent years.

Biologics such as recombinant proteins and peptides present multiple benefits, including heightened target specificity, good safety profiles, low toxicity, and reduced likelihood of off-target effects. Notably, many pharmaceutical firms are focusing on the advancement of innovative drug conjugates, including peptide drug conjugates, peptide therapeutics, and cell-penetrating peptides to address a wide array of diseases. Moreover, recent progress in this area has resulted in the authorization and clinical application of peptide medications for disorders such as type 2 diabetes, obesity, and several cancers. We are led to believe that the market is likely to achieve notable growth in the foreseeable future.

PEPTIDE THERAPEUTICS MARKET: KEY INSIGHTS

The report delves into the current state of the peptide therapeutics market and identifies potential growth opportunities within industry. Some key findings from the report include:
  • With 25 approved drugs and over 280 candidates under development, peptide therapeutics currently represent one of the fastest growing drug classes, capable of treating a diverse range of diseases.

  • The pipeline features a variety of peptides being evaluated for delivery via different routes, and mostly intended for treating metabolic and oncological disorders
  • In lieu of the growing competition from several viable candidate therapies, innovators are putting in significant efforts to ensure that their proprietary offerings are both clinically and commercially differentiated.
  • Over 1,200 peptide focused clinical trials have been registered across the world; presently, most of these studies are evaluating product candidates intended for the treatment of metabolic diseases.
  • The growing interest in this field is also evident in the increase in recent partnership activity; majority of the deals were focused on technology and / or product licensing.

  • Foreseeing promising returns, many public and private sector investors have invested over USD 7 billion, across more than 200 instances.

  • In order to tap into the lucrative opportunity in this rapidly growing market, several big pharma players have undertaken initiatives, ranging from proprietary product development to strategic investments, in this direction.
  • With a promising development pipeline and encouraging clinical outcomes, the peptide therapeutics market is anticipated to grow at an annualized rate of 6.8%, over the next decade.

PEPTIDE THERAPEUTICS MARKET: KEY SEGMENTS

Medium Size Peptides in the Peptide Therapeutics Industry Holds the Largest Share

In the current year, medium sized peptides capture the majority (close to 65% of the market) share. This is probably because medium-sized peptides (ranging from 10 to 40 amino acids) effectively strike a balance between larger proteins and smaller molecules. It is worth highlighting that, small peptides will grow at a CAGR of more than 20% during the forecast period, owing to the increasing usage in manufacturing target specific drugs.

Subcutaneous Route of Administration to Dominate the Peptide Therapeutics Market

The overall market is segmented into intravenous, oral, subcutaneous, topical, and others. In the current year, subcutaneous route of administration accounts for more than 65% of the overall market. The subcutaneous route can avoid the gastrointestinal tract and liver (first-pass metabolism), resulting in greater therapeutic effectiveness. Owing to the ongoing demand for non-invasive or target specific routes of administration, the topical route of administration is likely to grow at a CAGR of ~30% during the forecast period.

Metabolic Diseases Segment to Hold the Highest Peptide Therapeutics Market

Currently, the metabolic diseases segment is likely to capture more than 60% of the overall market share. This is attributed to the increasing need for peptide-based therapies aimed at addressing metabolic conditions like diabetes and obesity. Notably, the peptide therapeutics market for gastrointestinal diseases will expand with a higher CAGR of 25% during the forecast period.

North America to Propel in the Peptide Therapeutics Industry in the Coming Years

This segment highlights the distribution of market across various geographies, such as North America, Europe and Asia-Pacific. According to our projections, North America accounts for the majority of the market share in the current year, and this trend is unlikely to change in the future. According to the report of Centers for Disease Control and Prevention, nearly 129 million people in the United States have at least one or more chronic disease such as diabetes, obesity, heart disease, and hypertension. This is leading to growing demand for peptide therapeutics in this region. It is worth highlighting that the market in Asia-Pacific is likely to grow at a relatively higher CAGR during the forecast period.

Example Players in the Peptide Therapeutics Market

  • Apellis Pharmaceuticals
  • BioLineRx
  • Eli Lilly
  • FirstString Research
  • Novo Nordisk
  • Palatin Technologies
  • RegeneRx Biopharmaceuticals
  • Stealth BioTherapeutics
  • Takeda
  • Zealand Pharma

PEPTIDE THERAPEUTICS MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the peptide therapeutics market, focusing on key market segments, including [A] type of peptide, [B] route of administration, [C] key therapeutic area, [D] geographical regions.
  • Market Landscape: provides a detailed assessment of over 300 peptide-based therapies that are currently approved or are in different stages of development, based on several relevant parameters, such as [A] phase of development, [B] type of peptide, [C] route of administration, [D] key therapeutic areas, [E] year of establishment, [F] company size, and [G] location of headquarters.
  • Company Profiles: In-depth profiles of prominent players engaged in this domain, focusing on [A] year of establishment, [B] location of headquarters, [C] peptide details [D] recent developments and [E] an informed future outlook.
  • Big Pharma Initiatives: An analysis of top big biopharma players engaged in the field of therapeutic peptides, based on several parameters, including [A] number of amino acids, [B] route of administration and [C] therapeutic area.
  • Partnerships and Collaborations An insightful analysis of the partnerships and collaborations inked between stakeholders engaged in the peptide therapeutics market based on various relevant parameters, including [A] year of partnership, [B] type of partnership, [C] type of partner and [D] most active players.
  • Funding and Investment Analysis: A comprehensive examination of various funding and investments raised by developers of peptide therapeutics, based on relevant parameters, including [A] such as year of funding, [B] amount invested [C] type of funding, [D] regional distribution, and [E] most active players.
  • Clinical Trial Analysis: A detailed review of completed, ongoing, and planned clinical studies of various therapeutic peptides, based on relevant parameters, such as [A] trail registration year, [B] phase of development, [C] current trial status and [D] enrolled patient population.
  • Case Study 1: A case study focused on the role of service providers that operate within the peptide therapeutics market and captures information on the various CROs, CMOs and custom peptide manufacturers that are actively involved in this segment of the peptide therapeutics market.
  • Case Study 2: A case study presenting the key characteristics of novel peptides drugs, along with information on the applications, advantages and key challenges involved in their development processes.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What is the current global capacity of developers?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with the Research Team
  • Free Updated report if the report is 6-12 months old or older

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Peptides
3.3. Classification of Peptides
3.4. Modification of Peptides
3.4.1. N-Terminal Modifications
3.4.2. Internal Modifications
3.4.3. C-Terminal Modifications
3.4.4. Other Modifications
3.5. Evolution of Peptide Therapeutics
3.6. Design and Development of Peptide Therapeutics
3.6.1. Traditional versus Novel Peptide Technologies
3.7. Advantages and Disadvantages of Peptide Therapeutics
3.8. Applications of Peptide Therapeutics
3.9. Future Perspectives
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Peptide Therapeutics: Overall Market Overview
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Peptide
4.2.3. Analysis by Route of Administration
4.2.4. Analysis by Phase of Development and Route of Administration
4.2.5. Analysis by Therapeutic Area
4.2.6. Analysis by Phase of Development and Therapeutic Area
4.2.7. Analysis by Route of Administration and Therapeutic Area
4.2.8. Analysis by Phase of Development, Route of Administration and
Therapeutic Area (Grid Representation)
5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Peptide Therapeutics: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Geography
5.2.4. Analysis by Phase of Development and Geography (Logo Landscape)
5.2.5.Key Players: Analysis by Number of Product Candidates
5.3.Analysis by Company Size, Key Therapeutic Area and Geography (Heat
Map Representation)
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Apellis Pharmaceuticals
6.2.1. Company Overview
6.2.2 Pipeline Details
6.2.2. Recent Developments and Future Outlook
6.3. BioLineRx
6.3.1. Company Overview
6.3.2. Pipeline Details
6.3.3. Recent Developments and Future Outlook
6.4. Eli Lilly
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Pipeline Details
6.4.4. Recent Developments and Future Outlook
6.5. FirstString Research
6.5.1. Company Overview
6.5.2. Pipeline Details
6.5.3. Recent Developments and Future Outlook
6.6. Novo Nordisk
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Pipeline Details
6.6.4. Recent Developments and Future Outlook
6.7. Palatin Technologies
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Pipeline Details
6.7.4. Recent Developments and Future Outlook
6.8. RegeneRx Biopharmaceuticals
6.8.1. Company Overview
6.8.2. Pipeline Details
6.8.3. Recent Developments and Future Outlook
6.9. Stealth BioTherapeutics
6.9.1. Company Overview
6.9.2. Pipeline Details
6.9.3. Recent Developments and Future Outlook
6.10. Takeda
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Pipeline Details
6.10.4. Recent Developments and Future Outlook
6.11. Zealand Pharma
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Pipeline Details
6.11.4. Recent Developments and Future Outlook
7. PEPTIDE THERAPEUTICS FOCUSED INITIATIVES OF BIG PHARMA PLAYERS
7.1. Chapter Overview
7.2. Top Pharmaceutical Companies: Peptide Therapeutics Focused
Initiatives
7.2.1. Analysis by Number of Amino Acids
7.2.2. Analysis by Route of Administration
7.2.3. Analysis by Therapeutic Area
7.3. Benchmark Analysis of Key Parameters
7.3.1. Spider Web Analysis: Pipeline Strength
7.3.2. Spider Web Analysis: Partnerships and Collaborations
7.3.3. Spider Web Analysis: Funding and Investments
7.3.4. Spider Web Analysis: Clinical Trials
7.4. Benchmark Analysis of Big Pharmaceutical Players
7.4.1. Spider Web Analysis: Novo Nordisk
7.4.2. Spider Web Analysis: Amgen
7.4.3. Spider Web Analysis: Takeda
7.4.4. Spider Web Analysis: Eli Lilly
7.4.5. Spider Web Analysis: Johnson and Johnson
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Peptide Therapeutics: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.3.5. Analysis by Type of Partnership and Focus Area
8.3.6. Analysis by Type of Peptide
8.3.7. Analysis by Route of Administration
8.3.8. Analysis by Route of Administration and Geography
8.3.9. Analysis by Type of Partnership and Phase of Development
8.3.10. Analysis by Therapeutic Area
8.3.11. Analysis by Type of Partnership and Therapeutic Area
8.4. Most Active Players: Analysis by Number of Partnerships
8.5. Regional Analysis
8.5.1. Intracontinental and Intercontinental Agreements
8.5.2. Local and International Agreements
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Peptide Therapeutics: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Year and Type of Funding
9.3.5. Analysis of Amount Invested by Geography
9.3.6. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
9.3.7. Key Investors: Analysis by Number of Funding Instances
9.3.8. Analysis by Phase of Development
9.3.9. Analysis by Therapeutic Area
10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Peptide Therapeutics: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Phase
10.3.4. Analysis by Trial Recruitment Status
10.3.5. Analysis by Trial Registration Year and Enrolled Patient Population
10.3.6. Analysis by Study Design
10.3.7. Analysis by Type of Sponsor / Collaborator
10.3.8. Most Active Players: Analysis by Number of Registered Trials
10.3.9. Emerging Focus Area
10.3.10. Analysis by Therapeutic Area
10.3.11. Geographical Analysis by Number of Registered Trials
10.3.12. Geographical Analysis by Enrolled Patient Population
11. CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Methodology
11.2.1. Assumptions and Key Parameters
11.3. Affiliated Insights
11.3.1. Clinical and Commercial Attractiveness Analysis: Autoimmune Diseases
11.3.2. Clinical and Commercial Attractiveness Analysis: Central Nervous System (CNS) Diseases
11.3.3. Clinical and Commercial Attractiveness Analysis: Endocrine
Diseases
11.3.4. Clinical and Commercial Attractiveness Analysis: Gastrointestinal
Diseases
11.3.5. Clinical and Commercial Attractiveness Analysis: Genetic Diseases
11.3.6. Clinical and Commercial Attractiveness Analysis: Hematological
Diseases
11.3.7. Clinical and Commercial Attractiveness Analysis: Infectious Diseases
11.3.8. Clinical and Commercial Attractiveness Analysis: Inflammatory
Diseases
11.3.9. Clinical and Commercial Attractiveness Analysis: Metabolic Diseases
11.3.10. Clinical and Commercial Attractiveness Analysis: Oncological
Diseases
11.3.11. Clinical and Commercial Attractiveness Analysis: Ophthalmic
Diseases
11.3.12. Clinical and Commercial Attractiveness Analysis: Other Diseases
12. CASE STUDY: CONTRACT SERVICES LANDSCAPE
12.1. Chapter Overview
12.1.1. Chapter Overview
12.2. Role of Service Providers
12.2.1. List of Peptide CROs
12.2.2. List of Platform Providers
12.2.3. List of Peptide CMOs
12.2.3.1. List of Custom Peptide Manufacturers
12.3. Advantages of Outsourcing
12.4. Risks and Challenges Associated with Outsourcing
13. CASE STUDY: NOVEL PEPTIDE THERAPEUTICS
13.1. Chapter Overview
13.2. Overview of Novel Peptide Therapeutics
13.3. Advantages and Applications of Novel Peptide Therapeutics
13.4. Key Challenges Associated with Novel Peptide Therapeutics
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Global Peptide Therapeutics Market, till 2030
14.4.1. Global Peptide Therapeutics Market, till 2030: Distribution by Type of Peptide
14.4.2. Peptide Therapeutics Market, till 2030: Distribution by Number of Amino Acids
14.4.3. Peptide Therapeutics Market, till 2030: Distribution by Route of Administration
14.4.4. Peptide Therapeutics Market, till 2030: Distribution by Geography
14.4.5. Peptide Therapeutics Market, till 2030: Distribution by Key Therapeutic Area
14.5. Autoimmune Diseases
14.5.1. Value Creation Analysis
14.5.2. Sales Forecast for Approved Peptide Therapeutics
14.5.2.1. Tymlos ®
14.5.3. Sales Forecast for Clinical Peptide Therapeutics
14.5.3.1. Ampion / DMI 9523
14.5.3.2. TBRIA
14.6. Cardiovascular Diseases
14.6.1. Value Creation Analysis
14.6.2. Sales Forecast for Approved Peptide Therapeutics
14.6.2.1. Giapreza ®
14.7. CNS Diseases
14.7.1. Value Creation Analysis
14.7.2. Sales Forecast for Clinical Peptide Therapeutics
14.7.2.1. Nerinitide
14.7.2.2. Rybelsus ®
14.8. Dermatological Diseases
14.8.1. Value Creation Analysis
14.8.2. Sales Forecast for Approved Peptide Therapeutics
14.8.2.1. Melgain
14.9. Endocrine Diseases
14.9.1. Value Creation Analysis
14.9.2. Sales Forecast for Approved Peptide Therapeutics
14.9.2.1. Parsabiv ®
14.9.2.2. Lupykins
14.9.3. Sales Forecast for Clinical Peptide Therapeutics
14.9.3.1. Difelikefalin / KORSUVA / Oral CR845
14.10. Gastrointestinal Diseases
14.10.1. Value Creation Analysis
14.10.2. Sales Forecast for Approved Peptide Therapeutics
14.10.2.1. Gattex ®
14.10.2.2. Trulance ®
14.10.3. Sales Forecast for Clinical Peptide Therapeutics
14.10.3.1. Glepaglutide / ZP1848
14.10.3.2. Larazotide / INN-202
14.11. Genetic Diseases
14.11.1. Value Creation Analysis
14.11.2. Sales Forecast for Approved Peptide Therapeutics
14.11.2.1. Scenesse ®
14.11.3. Sales Forecast for Clinical Peptide Therapeutics
14.11.3.1. Elamipretide / MTP-131
14.11.3.2. Ninlaro ®
14.11.3.3. Vosoritide / BMN 111
14.11.3.4. Zilucoplan / RA101495
14.12. Hematological Diseases
14.12.1. Value Creation Analysis
14.12.2. Sales Forecast for Clinical Peptide Therapeutics
14.12.2.1. Pegcetacoplan / APL-2
14.13. Infectious Diseases
14.13.1. Value Creation Analysis
14.13.2. Sales Forecast for Approved Peptide Therapeutics
14.13.2.1. Solnatide
14.13.3. Sales Forecast for Clinical Peptide Therapeutics
14.13.3.1. Aikening / Albuvirtide
14.13.3.2. Reltecimod
14.14. Inflammatory Diseases
14.14.1. Value Creation Analysis
14.14.2. Sales Forecast for Clinical Peptide Therapeutics
14.14.2.1. Lupuzor
14.15. Metabolic Diseases
14.15.1. Value Creation Analysis
14.15.2. Sales Forecast for Approved Peptide Therapeutics
14.15.2.1. Adlyxin ®
14.15.2.6. Imcivree ™
14.15.2.3. Mycapssa ®
14.15.2.5. Ozempic ®
14.15.2.4. Rybelsus ®
14.15.2.7. Tanzeum ®
14.15.2.8. Tresiba ®
14.15.2.2. Trulicity ®
14.15.2.10. Zegalogue ®
14.15.3. Sales Forecast for Clinical Peptide Therapeutics
14.15.3.1. Imcivree ™
14.15.3.2. Ozempic
14.15.3.3. Tirzepatide / LY3298176
14.16. Oncological Diseases
14.16.1. Value Creation Analysis
14.16.2. Sales Forecast for Approved Peptide Therapeutics
14.16.2.1. Aplidin ®
14.16.2.2. Lupron ®
14.16.2.3. Lutathera ®
14.16.2.4. Ninlaro ®
14.16.3. Sales Forecast for Clinical Peptide Therapeutics
14.16.3.1. Balixafortide / POL6326
14.16.3.2. Dusquetide / SGX942
14.16.3.3. Motixafortide / BL-8040
14.17. Ophthalmic Diseases
14.17.1. Value Creation Analysis
14.17.2. Sales Forecast for Clinical Peptide Therapeutics
14.17.2.1. RGN-259 / GBT-201
14.17.2.2. Pegcetacoplan / APL-2
14.17.2.3. XG-102
14.19. Other Diseases
14.19.1. Value Creation Analysis
14.19.2. Sales Forecast for Approved Peptide Therapeutics
14.19.2.1. Lupron ®
14.19.2.2. Vyleesi ™
14.19.2.3. Xylentra ™
14.19.3. Sales Forecast for Clinical Peptide Therapeutics
14.19.3.1. BP-101
14.19.3.2. Granexin
14.19.3.3. Ensereptide / PXL01
15. CONCLUDING REMARKS
15.1. Chapter Overview
16. APPENDIX I: LIST OF APPROVED PEPTIDE THERAPEUTICS17. APPENDIX II: TABULATED DATA18. APPENDIX III: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Peptide Modification Techniques
Figure 3.2 Historical Timeline of Peptide Therapeutics
Figure 4.1 Peptide Therapeutics: Distribution by Phase of Development
Figure 4.2 Peptide Therapeutics: Distribution by Type of Peptide
Figure 4.3 Peptide Therapeutics: Distribution by Route of Administration
Figure 4.4 Peptide Therapeutics: Distribution by Phase of Development and Route of Administration
Figure 4.5 Peptide Therapeutics: Distribution by Therapeutic Area
Figure 4.6 Peptide Therapeutics: Distribution by Phase of Development and Therapeutic Area
Figure 4.7 Peptide Therapeutics: Distribution by Route of Administration and Key Therapeutic Area
Figure 4.8 Grid Representation: Distribution by Phase of Development, Route of Administration and Key Therapeutic Area
Figure 5.1 Peptide Therapeutics Developers: Distribution by Year of Establishment
Figure 5.2 Peptide Therapeutics Developers: Distribution by Company Size
Figure 5.3 Peptide Therapeutics Developers: Distribution by Geography
Figure 5.4 Regional Landscape: Distribution of Peptide Therapeutics Developers by Phase of Development and Geography
Figure 5.5 Peptide Therapeutics Developers: Key Players
Figure 5.6 Peptide Therapeutics Developers: Distribution by Key Players and Phase of Development
Figure 5.7 Heat Map Representation: Distribution by Company Size, Key Therapeutic Area and Geography
Figure 6.1 Eli Lilly: Annual Revenues, FY 2015 Onwards (USD Million)
Figure 6.2 Novo Nordisk: Annual Revenues, FY 2015 Onwards (DKK Million)
Figure 6.3 Palatin Technologies: Annual Revenues, FY 2015 Onwards (USD Million)
Figure 6.4 Takeda: Annual Revenues, FY 2015 Onwards (JPY Million)
Figure 6.5 Zealand Pharma: Annual Revenues, FY 2015 Onwards (DKK Million)
Figure 7.1 Harvey Ball Analysis: Big Pharma Investment Summary
Figure 7.2 Big Pharma Players: Distribution by Number of Amino Acids
Figure 7.3 Big Pharma Players: Distribution by Route of Administration
Figure 7.4 Big Pharma Players: Distribution by Therapeutic Area
Figure 7.5 Spider Web Analysis: Pipeline Strength
Figure 7.6 Spider Web Analysis: Partnerships and Collaborations
Figure 7.7 Partnerships and Collaborations: Distribution by Year and Type of Partnership Undertaken by Big Pharma Players
Figure 7.8 Spider Web Analysis: Funding and Investments
Figure 7.9 Spider Web Analysis: Clinical Trials
Figure 7.10 Spider Web Analysis: Novo Nordisk
Figure 7.11 Spider Web Analysis: Amgen
Figure 7.12 Spider Web Analysis: Takeda
Figure 7.13 Spider Web Analysis: Eli Lilly
Figure 7.14 Spider Web Analysis: Johnson and Johnson
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Focus Area
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Focus Area
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Peptide
Figure 8.7 Partnerships and Collaborations: Distribution by Route of Administration
Figure 8.8 Partnerships and Collaborations: Distribution by Route of Administration and Geography
Figure 8.9 Partnerships and Collaborations: Distribution by Type of Partnership and Phase of Development
Figure 8.10 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.11 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 8.12 Most Active Players: Distribution by Number of Partnerships
Figure 8.13 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 8.14 Partnerships and Collaborations: Local and International Agreements
Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Distribution by Number of Instances, since 2015
Figure 9.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, since 2015 (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, since 2015
Figure 9.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, since 2015 (USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution by Year and Type of Funding, since 2015
Figure 9.6 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested, since 2015 (USD Million)
Figure 9.7 Funding and Investment Analysis: Summary of Investments, since 2015 (USD Million)
Figure 9.8 Funding and Investment Analysis: Distribution by Geography
Figure 9.9 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 9.10 Most Active Players: Distribution by Number of Funding Instances
Figure 9.11 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 9.12 Funding and Investment Analysis:* Distribution by Type of Investors
Figure 9.13 Funding and Investment Analysis: Distribution by Leading Investors
Figure 9.13 Funding and Investment Analysis: Distribution of Instances by Phase of Development
Figure 9.14 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 10.1 Clinical Trial Analysis: Scope and Methodology
Figure 10.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Figure 10.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 10.7 Clinical Trial Analysis: Distribution by Study Design
Figure 10.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.9 Most Active Players: Distribution by Number of Registered Trials
Figure 10.10 Clinical Trial Analysis: Emerging Focus Area
Figure 10.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 10.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 11.1 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Autoimmune Diseases
Figure 11.2 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: CNS Diseases
Figure 11.3 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Endocrine Diseases
Figure 11.4 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Gastrointestinal Diseases
Figure 11.5 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Genetic Diseases
Figure 11.6 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Hematological Diseases
Figure 11.7 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Infectious Diseases
Figure 11.8 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Inflammatory Diseases
Figure 11.9 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Metabolic Diseases
Figure 11.10 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Oncological Diseases
Figure 11.11 Clinical and Commercial Attractiveness Analysis of Phase III Molecules: Ophthalmic Diseases
Figure 11.12 Clinical and Commercial Attractiveness Analysis: Phase III Molecules: Other Diseases
Figure 14.1 Global Peptide Therapeutics Market, till 2030 (USD Billion)
Figure 14.2 Peptide Therapeutics Market: Distribution by Type of Peptide, till 2030
Figure 14.3 Peptide Therapeutics Market: Distribution by Route of Administration, till 2030
Figure 14.4 Peptide Therapeutics Market: Distribution by Geography, till 2030
Figure 14.5 Peptide Therapeutics Market: Distribution by Key Therapeutic Area, till 2030
Figure 14.6 Peptide Therapeutics Market for Autoimmune Diseases, till 2030 (USD Billion)
Figure 14.7 Peptide Therapeutics Market for Cardiovascular Diseases, till 2030 (USD Billion)
Figure 14.8 Peptide Therapeutics Market for CNS Diseases, till 2030 (USD Billion)
Figure 14.9 Peptide Therapeutics Market for Dermatological Diseases, till 2030 (USD Billion)
Figure 14.10 Peptide Therapeutics Market for Endocrine Diseases, till 2030 (USD Billion)
Figure 14.11 Peptide Therapeutics Market for Gastrointestinal Diseases, till 2030 (USD Billion)
Figure 14.12 Peptide Therapeutics Market for Genetic Diseases, till 2030 (USD Billion)
Figure 14.13 Peptide Therapeutics Market for Hematological Diseases, till 2030 (USD Billion)
Figure 14.14 Peptide Therapeutics Market for Infectious Diseases, till 2030 (USD Billion)
Figure 14.15 Peptide Therapeutics Market for Inflammatory Diseases, till 2030 (USD Billion)
Figure 14.16 Peptide Therapeutics Market for Metabolic Diseases, till 2030 (USD Billion)
Figure 14.17 Peptide Therapeutics Market for Oncological Diseases, till 2030 (USD Billion)
Figure 14.18 Peptide Therapeutics Market for Ophthalmic Diseases, till 2030 (USD Billion)
Figure 14.19 Peptide Therapeutics Market for Other Diseases, till 2030 (USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 13therapeutics
  • 7 Med Health Ventures
  • 9 Meters Biopharma
  • Abbott
  • Abingworth
  • Acorn Bioventures
  • ACT Capital Management
  • Adage Capital Management
  • Adams Street Partners
  • Advanced Accelerator Applications
  • Aileron Therapeutics
  • AJU IB Investment
  • Akashi Therapeutics
  • Alexion Pharmaceuticals
  • Allysta Pharmaceuticals
  • Alphabet venture arm
  • Altimmune
  • Amgen
  • Amolyt Pharma
  • Ampio Pharmaceuticals
  • Amyndas Pharmaceuticals
  • Andera Partners
  • Angiochem
  • Anji Pharmaceuticals
  • AOP Orphan Pharmaceuticals
  • Apellis Pharmaceuticals
  • Apeptico
  • APIM Therapeutics
  • Apitope
  • Aquestive Therapeutics
  • Arch Biopartners
  • ARCH Venture Partners
  • Arix Bioscience
  • Asahi Kasei
  • AsclepiX Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Atlas Venture
  • Atox Bio
  • Aurinia Pharmaceuticals
  • Avilex Pharma
  • Avion Pharmaceuticals
  • Barer & Son Capital
  • Bayer
  • Becker
  • Belfius
  • Bergens forskningsstiftelse
  • Beth Israel Deaconess Medical Center
  • Better Ventures
  • Bicycle Therapeutics
  • Biogenosis
  • Bioglan
  • BioLineRx
  • Biolingus
  • Biomarck Pharmaceuticals
  • BioMarin Pharmaceutical
  • Biomedical Advanced Research and Development Authority (BARDA)
  • BiomedInvest
  • BioMedPartners
  • Bios Partners
  • Biosciences Research & Commercialization Center
  • BioSkin
  • BL&H
  • Boehringer Ingelheim
  • Boehringer Ingelheim Venture Fund
  • Boryung Pharmaceutical
  • Bossa Ventures
  • Boston Therapeutics
  • Bpifrance
  • Brightlands Life Sciences Ventures
  • Bristol Myers Squibb
  • Buttonwood
  • BVF Partners
  • Cambridge Innovation Capital (CIC)
  • Canaccord Genuity
  • CanBas
  • Cancer Research UK
  • Capital Community Angels
  • Cara Therapeutics
  • CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator)
  • Cardiorentis
  • Carmot Therapeutics
  • Catalent
  • Cathay Venture
  • Celgene
  • Cellastra
  • Cend Therapeutics
  • Chiasma Pharma
  • Chondropeptix
  • Chrysalis BioTherapeutics
  • Clinical Research Center for Hair and Skin
  • Clinuvel Pharmaceuticals
  • CohBar
  • Cold Spring Harbor Laboratory
  • Constant Therapeutics
  • Contura
  • Cormorant Asset Management
  • CureDM
  • Curonz
  • Cutanea Life Sciences
  • Cystic Fibrosis Foundation Therapeutics
  • Cytovation
  • Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
  • Deerfield Management
  • Diabetology
  • Diapin Therapeutics
  • E&Investment
  • Eczacibasi
  • Elan Pharmaceuticals
  • Eli Lilly
  • Endo Ventures
  • Entera Bio
  • Enteris BioPharma
  • Epidarex Capital
  • Epimede
  • Eshelman Ventures
  • Esperance Pharmaceuticals
  • European Commission
  • F2 Capital
  • F4 Pharma
  • Fannin Partners
  • Ferring Pharmaceuticals
  • First In Ventures
  • FirstString Research
  • Follicum
  • Foresite Capital
  • Founders Fund
  • Fountain Healthcare Partners
  • F-Prime Capital Partners
  • Frontier Biotechnologies
  • FUJIFILM Toyama Chemical
  • Genentech
  • Genervon Biopharmaceuticals
  • GeneScience
  • Genus Oncology
  • GF Ventures
  • Gila Therapeutics
  • GlaxoSmithKline
  • GlioCure
  • GlycoNet
  • Google Ventures
  • Government of Canada
  • Government of Quebec
  • Grand Oaks Capital
  • G-tree BNT
  • GYRUS Pharma
  • HBG Beteiligungs- und Beratungsgesellschaft
  • HealthCare Royalty Partners (HCR)
  • Healthlink Capital
  • Hercules Capital
  • Hestia Investments
  • HighTide Therapeutics
  • Hillhouse Capital Group
  • Horizon Technology Finance
  • Horizons Ventures
  • iBio
  • ILC Therapeutics
  • Imcyse
  • ImmuPharma
  • InCube Ventures
  • InFocus Capital Partners
  • InnoBio 2
  • Innovate UK
  • Inotrem
  • Integra Holdings
  • Inter-American Development Bank (IDB)
  • InterK Peptide Therapeutics
  • Intervest
  • Invest Michigan
  • Investinor
  • Invus
  • Ipsen
  • Issar Pharmaceuticals
  • Janssen Biotech
  • Janssen Pharmaceuticals
  • JDRF
  • Jennison Associates
  • Johnson & Johnson
  • Kairos Ventures
  • Kaitai Capital
  • Kalos Therapeutics
  • KeyBioscience
  • Knoll Capital Management
  • KPC Pharmaceuticals
  • Kreos Capital
  • KU Leuven
  • Kurma Partners
  • L1 Capital Global Opportunities Master Fund
  • La Jolla Pharmaceutical
  • Lanstead Capital
  • Lassogen
  • Lincoln Park Capital Fund
  • Lind Global Macro Fund
  • LipimetiX Development
  • Live Like Bella® Foundation
  • Longevity Biotech
  • Longwood Fund
  • Lonza
  • LRM Funds
  • LSP
  • Lundbeckfonden Ventures
  • Madryn Asset Management
  • Maven Investment Partners
  • Maxim Group
  • MEDARVA Foundation
  • MedImmune
  • Mediolanum Farmaceutici
  • Megapharm
  • MElkin Pharmaceuticals
  • Merck
  • Merck Sharp & Dohme (MSD)
  • MeSCue-Janusys
  • Michigan Capital Network Venture Fund III
  • Mitsubishi Tanabe Pharma
  • Morningside Ventures
  • MPM Capital
  • Nan Fung Technology’s Pivotal Beta
  • Nanomerics
  • National Cancer Institute (NCI)
  • National Eye Institute (NEI)
  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Dental and Craniofacial Research (NIDCR)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Institutes of Health (NIH)
  • National Multiple Sclerosis Society
  • National Research Council Canada
  • Neuro-Bio
  • NeuroRx
  • New Enterprise Associates
  • NextPharma
  • NoNO
  • Noshaq
  • NovaCell Technology
  • Novartis
  • Novartis Venture Fund
  • Novo Nordisk
  • Novo Ventures
  • NV Industriebank LIOF
  • Oncology Pharma
  • Oncopeptides
  • ONL Therapeutics
  • Onyx Therapeutics
  • OPKO Health
  • Oramed Pharmaceuticals
  • OrbiMed
  • Otsuka Pharmaceutical
  • Ovoca Bio
  • Oxalo Therapeutics
  • Oxurion
  • PAION
  • Palatin Technologies
  • Park West Asset Management
  • Partners Innovation Fund
  • PEP-Therapy
  • PeptiDream
  • Peptilogics
  • Peptron
  • Perceptive Xontogeny Venture Fund
  • Pfizer
  • Pfizer Venture Investments
  • Pharma Research Products
  • PharmaMar
  • Pharmstandard International
  • Piedmont Capital Partners
  • PIN Pharma
  • Ping An Ventures
  • Pint Pharma
  • Playground Global
  • PMV
  • Polyphor
  • Pontifax
  • Praxis Pharmaceutical
  • Presight Capital
  • Priavoid
  • proDERM
  • ProLynx
  • ProMore Pharma
  • ProNeurogen
  • Protagonist Therapeutics
  • Protagenic Therapeutics
  • Proteimax
  • PSQ Capital
  • Pulmotect
  • Qilu Pharmaceutical
  • Quaker Partners
  • Quantum Leap Healthcare Collaborative (QLHC)
  • Quartesian
  • Radius Health
  • Rani Therapeutics
  • Rapha Capital Management
  • RegeneRx Biopharmaceuticals
  • ReGenTree
  • ReumaNederland
  • Rhythm Pharmaceuticals
  • Riesner Verwaltungs
  • Roche
  • Rock Springs Capital Management
  • Salem Partners
  • Salix Pharmaceuticals
  • Sanofi
  • Sanofi-Aventis
  • Santhera Pharmaceuticals
  • Sapience Therapeutics
  • Sarsia Seed
  • Satter Medical Technology Partners
  • SciClone Pharmaceuticals
  • Scios (Acquired by Johnson & Johnson)
  • Seachaid Pharmaceuticals
  • Sectoral Asset Management
  • Serpin Pharma
  • Seventure Partners
  • SFJ Pharmaceuticals
  • Shanghai Fosun Pharmaceutical
  • Shire
  • SIRS Therapeutics
  • Société Fédérale de Participations et d'Investissement (SFPI)
  • Société Régionale d'Investissement de Wallonie (SRIW)
  • Sofinnova Ventures
  • Soligenix
  • Sophos Capital
  • Soricimed Biopharma
  • Specialised Therapeutics
  • SR One
  • Stealth BioTherapeutics
  • SV Health Investors
  • Swedish Orphan Biovitrum (SOBI)
  • SYNG Pharmaceuticals
  • TaiAn Technologies
  • Takeda
  • Tarsa Therapeutics
  • TearSolutions
  • Technomark Life Sciences
  • TEDCO
  • Televenture (Funded through NIK III)
  • Texas A&M University Health Science Center
  • The Column Group
  • The Leona M. and Harry B. Helmsley Charitable Trust
  • University of Bath
  • The University of Chicago Innovation Fund
  • The University of Texas MD Anderson Cancer Center
  • TheraSource
  • Theratechnologies
  • Third Rock Ventures
  • Topas Therapeutics
  • Tsingyuan Ventures
  • TTY Biopharm
  • TwoToBiotech
  • UCB Pharma
  • University of Freiburg
  • University of Missouri Research Reactor (MURR®)
  • University of St Andrews
  • US Department of Defense
  • UVA Seed Fund
  • ValiRx
  • Vault Pharma
  • Vaxeal
  • venBio Global Strategic Fund
  • Ventac Partners
  • VentureHealth
  • Vertex Ventures
  • Vesalius Biocapital
  • Viatem
  • Vifor Pharma
  • Vinnova
  • Virtus Inspire Ventures
  • Vivo Capital
  • VTC Innovation Fund
  • Wales Life Sciences Fund
  • West Midlands Academic Health Science Network (WMAHSN)
  • WuXi AppTec
  • Wyvern
  • Xigen
  • YuYang D&U
  • Zealand Pharma
  • Zucara Therapeutics

Methodology

 

 

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages250
PublishedDecember 2025
Forecast Period2025 - 2035
Estimated Market Value ( USD ) in 2025 $ 84.2 Billion
Forecasted Market Value ( USD ) by 2035 $ 162.4 Billion
Compound Annual Growth Rate6.8%
Regions CoveredGlobal

Related Topics

Related Reports

Peptide Therapeutics Market Size, Share, Trends and Forecast by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region, 2025-2033 - Product Image

Peptide Therapeutics Market Size, Share, Trends and Forecast by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region, 2025-2033

  • Report
  • 139 Pages
  • Global
From
Peptide Therapeutics Market Report and Forecast 2023-2031 - Product Image

Peptide Therapeutics Market Report and Forecast 2023-2031

  • Report
  • 147 Pages
  • Global
From
Peptide Therapeutics Market - Global Forecast 2025-2032 - Product Image

Peptide Therapeutics Market - Global Forecast 2025-2032

  • Report
  • 194 Pages
  • Global
From
Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029 - Product Image

Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029

  • Report
  • 1800 Pages
  • Global
From
Peptide Therapeutics Market Size, Share & Trends Analysis Report by Application, Type (Innovative, Generic), Type of Manufacturer (Inhouse, Outsourced), Route of Administration, Synthesis Technology, and Region with Growth Forecasts, 2025-2030 - Product Image

Peptide Therapeutics Market Size, Share & Trends Analysis Report by Application, Type (Innovative, Generic), Type of Manufacturer (Inhouse, Outsourced), Route of Administration, Synthesis Technology, and Region with Growth Forecasts, 2025-2030

  • Report
  • 153 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.